Targeting GSK3β for the treatment of diseases has raised concerns regarding the development and progression of cancer due to the promotion of proto-oncogenic pathways mediated by Wnt/β-catenin and Hh signaling [6,13,14]. Here, GSK3B is linked to cancer.